Boston Scientific Co. (NYSE:BSX) EVP Sells $517,579.96 in Stock

Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $74.12, for a total value of $517,579.96. Following the sale, the executive vice president now owns 40,188 shares in the company, valued at approximately $2,978,734.56. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Wendy Carruthers also recently made the following trade(s):

• On Monday, July 1st, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The stock was sold at an average price of $77.30, for a total transaction of $539,785.90.
• On Monday, June 3rd, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The shares were sold at an average price of $75.33, for a total transaction of $526,029.39.

Boston Scientific Trading Down 0.9 %

NYSE BSX opened at $74.50 on Friday. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $79.43. The company has a fifty day simple moving average of $76.42 and a two-hundred day simple moving average of $70.91. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. The stock has a market cap of $109.30 billion, a P/E ratio of 62.61, a P/E/G ratio of 2.49 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. The company had revenue of $4.12 billion during the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a return on equity of 16.80% and a net margin of 12.00%. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the business posted $0.53 EPS. On average, analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the topic of a number of research analyst reports. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. JPMorgan Chase & Co. raised their price objective on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, July 25th. Truist Financial increased their price target on Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Deutsche Bank Aktiengesellschaft lifted their price objective on Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a report on Thursday, July 25th. Finally, UBS Group boosted their price target on shares of Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $84.76.

Institutional Investors Weigh In On Boston Scientific

A number of large investors have recently bought and sold shares of the company. Triad Wealth Partners LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at $26,000. First Foundation Advisors acquired a new stake in Boston Scientific during the 1st quarter worth about $25,000. Eagle Bay Advisors LLC raised its stake in shares of Boston Scientific by 542.1% during the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 309 shares during the last quarter. Lynx Investment Advisory acquired a new position in shares of Boston Scientific in the 2nd quarter valued at about $30,000. Finally, RiverPark Advisors LLC purchased a new stake in shares of Boston Scientific in the first quarter worth about $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.